Neurobiology of Huntington's Disease Applications to Drug Discovery
Highlighting advances in the discovery and development of new drug therapies for neurodegenerative disorders, Neurobiology of Huntington's Disease focuses on the many aspects of the research on drugs to treat Huntington's disease. It discusses genetics, genomics, and proteomics, and the la...
Saved in:
Main Authors | , |
---|---|
Format | eBook |
Language | English |
Published |
Milton
CRC Press
2011
Taylor & Francis Group |
Edition | 1 |
Series | Frontiers in neuroscience |
Subjects | |
Online Access | Get full text |
ISBN | 0849390001 9780849390005 |
DOI | 10.1201/EBK0849390005 |
Cover
Abstract | Highlighting advances in the discovery and development of new drug therapies for neurodegenerative disorders, Neurobiology of Huntington's Disease focuses on the many aspects of the research on drugs to treat Huntington's disease. It discusses genetics, genomics, and proteomics, and the latest in high-throughput and high-content screening. The authors provide introductory background as well as highly sophisticated information on current and future directions of research. Exploring the interplay between academic and industrial research, the investment community, and non-profit contributors, the book also examines the practical realities of preclinical testing, clinical testing strategies, and, ultimately, clinical usage. |
---|---|
AbstractList | In 1993, the genetic mutation responsible for Huntington's disease (HD) was identified. Considered a milestone in human genomics, this discovery has led to nearly two decades of remarkable progress that has greatly increased our knowledge of HD, and documented an unexpectedly large and diverse range of biochemical and genetic perturbations that seem to result directly from the expression of the mutant huntingtin gene.
Neurobiology of Huntington's Disease: Applications to Drug Discoverypresents a thorough review of the issues surrounding drug discovery and development for the treatment of this paradigmatic neurodegenerative disease. Drawing on the expertise of key researchers in the field, the book discusses the basic neurobiology of Huntington's disease and how its monogenic nature confers enormous practical advantages for translational research, including the creation of robust experimental tools, models, and assays to facilitate discovery and validation of molecular targets and drug candidates for HD. Written to support future basic research as well as drug development efforts, this volume:
Covers the latest research approaches in genetics, genomics, and proteomics, including high-throughput and high-content screening
Highlights advances in the discovery and development of new drug therapies for neurodegenerative disorders
Examines the practical realities of preclinical testing, clinical testing strategies, and, ultimately, clinical usage
While the development of effective drug treatments for Huntington's disease continues to be tremendously challenging, a highly interactive and cooperative community of researchers and clinical investigators now brings us to the threshold of potential breakthroughs in the quest for therapeutic agents. The impressive array of drug discovery resources outlined in the text holds much promise for treating this devastating disease, providing hope to long-suffering Huntington's disease patients and their families. Highlighting advances in the discovery and development of new drug therapies for neurodegenerative disorders, Neurobiology of Huntington's Disease focuses on the many aspects of the research on drugs to treat Huntington's disease. It discusses genetics, genomics, and proteomics, and the latest in high-throughput and high-content screening. The authors provide introductory background as well as highly sophisticated information on current and future directions of research. Exploring the interplay between academic and industrial research, the investment community, and non-profit contributors, the book also examines the practical realities of preclinical testing, clinical testing strategies, and, ultimately, clinical usage. |
Author | Lo, Donald C Hughes, Robert E |
Author_xml | – sequence: 1 fullname: Lo, Donald C – sequence: 2 fullname: Hughes, Robert E |
BookMark | eNpVkL1PwzAQxY34EG3pyN4BqWIonB078Y20BIqoYEGIzXISp4QGG-y0pf89KYWBW06n97t7p9clB9ZZQ8gphQvKgF6m43uQHCMEALFHusAZUsaYeNlvhz-FHpGORKRCxMCOST-EN9guMIxAdMjZg1l6l1WudvPNwJWD6dI2lZ03zg7D4LoKRgdzQg5LXQfT_-098nyTPk2mo9nj7d3kajbSLEb6Ncq5SRLEWItCcokJjXMhZNlWVgJmArksIgm8TCjHREeUSRGJnAKPDS9QRz1yvjusw8Ksw6urm6BWtcmcWwSFiaSctc9LJmTLDnfsh3efSxMa9YPlxjZe1yodTyiHeOvQI-mOrGzp_LteO18XqtGb2vnSa5tXYWdAQW2TVf-SVSvjQ-Usi74BdC5riw |
ContentType | eBook |
Copyright | 2011 by Taylor & Francis Group, LLC |
Copyright_xml | – notice: 2011 by Taylor & Francis Group, LLC |
DEWEY | 616.85107 |
DOI | 10.1201/EBK0849390005 |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISBN | 042912225X 9781420008258 9780429122255 1420008250 |
Edition | 1 |
Editor | Lo, Donald C. Hughes, Robert E. |
Editor_xml | – sequence: 1 givenname: Donald C. surname: Lo fullname: Lo, Donald C. – sequence: 2 givenname: Robert E. surname: Hughes fullname: Hughes, Robert E. |
ExternalDocumentID | 9781420008258 EBC1406285 10_1201_EBK0849390005_version2 |
GroupedDBID | 20A 5~G AABBV ABEQL ABHFA ABXRF ACBYE ADQWE ADYHE AEUHU AINFC AIXXW AKSCQ ALMA_UNASSIGNED_HOLDINGS ATPON AXE AXO AZZ BBABE BPDOF CZQ CZZ EBATF ENV INALI JG1 JTX MYL NEQ S.C ABYEM ABYSD AXTGW |
ID | FETCH-LOGICAL-a2691x-c4e77996a5d8489716c558ffffbf09b5948d3804f71497a3128535c1046e4d9a3 |
ISBN | 0849390001 9780849390005 |
IngestDate | Fri Nov 08 02:47:37 EST 2024 Fri May 30 21:11:50 EDT 2025 Tue Aug 19 03:07:41 EDT 2025 |
IsPeerReviewed | false |
IsScholarly | false |
Keywords | Htt Fragment Hd Subject Expand CAG Repeat Mutant Huntingtin Mutant Htt Hd Model Ef Cacy CAG Expansion Repeat Length Transgenic Mouse CAG Repeat Length RVG Peptide Hd Mouse polyQ Disease Manifest Hd Hd Patient Hd Therapy CAG Repeat Hd Pathogenesis Wild Type Htt Target Validation Ef Cacy Studies Antisense Oligonucleotide Hd Mouse Model |
LCCallNum_Ident | RC394.H85 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-a2691x-c4e77996a5d8489716c558ffffbf09b5948d3804f71497a3128535c1046e4d9a3 |
OCLC | 899155602 |
PQID | EBC1406285 |
PageCount | 342 |
ParticipantIDs | askewsholts_vlebooks_9781420008258 proquest_ebookcentral_EBC1406285 informaworld_taylorfrancisbooks_10_1201_EBK0849390005_version2 |
PublicationCentury | 2000 |
PublicationDate | 2011 2010 2010-07-02 |
PublicationDateYYYYMMDD | 2011-01-01 2010-01-01 2010-07-02 |
PublicationDate_xml | – year: 2011 text: 2011 |
PublicationDecade | 2010 |
PublicationPlace | Milton |
PublicationPlace_xml | – name: Milton |
PublicationSeriesTitle | Frontiers in neuroscience |
PublicationYear | 2011 2010 |
Publisher | CRC Press Taylor & Francis Group |
Publisher_xml | – name: CRC Press – name: Taylor & Francis Group |
SSID | ssj0000529305 ssib056456610 |
Score | 1.8463413 |
Snippet | Highlighting advances in the discovery and development of new drug therapies for neurodegenerative disorders, Neurobiology of Huntington's Disease focuses on... In 1993, the genetic mutation responsible for Huntington's disease (HD) was identified. Considered a milestone in human genomics, this discovery has led to... |
SourceID | askewsholts proquest informaworld |
SourceType | Aggregation Database Publisher |
SubjectTerms | Huntington's disease Neuropharmacology |
Subtitle | Applications to Drug Discovery |
TableOfContents | Front cover -- Contents -- Series Preface -- Preface -- Editors -- Contributors -- Chapter 1: Huntington's Disease -- Chapter 2: Huntington's Disease Pathogenesis -- Chapter 3: Protein Interactionsand Target Discovery inHuntington's Disease -- Chapter 4: Target Validation forHuntington's Disease -- Chapter 5: High-Throughput andHigh-Content Screeningfor Huntington'sDisease Therapeutics -- Chapter 6: Value of InvertebrateGenetics and Biology toDevelop Neuroprotectiveand Preventive Medicinein Huntington's Disease -- Chapter 7: Mouse Models forValidating PreclinicalCandidates forHuntington's Disease -- Chapter 8: PharmaceuticalDevelopment forHuntington's Disease -- Chapter 9: RNA- and DNABasedTherapies forHuntington's Disease -- Chapter 10: Recombinant Intrabodiesas Molecular Tools andPotential Therapeuticsfor Huntington's Disease -- Chapter 11: Biomarkers to Enablethe Developmentof NeuroprotectiveTherapies forHuntington's Disease -- Chapter 12: Huntington's Disease -- Index -- Color Inserts: -- Back cover |
Title | Neurobiology of Huntington's Disease |
URI | https://www.taylorfrancis.com/books/9780429122255 https://ebookcentral.proquest.com/lib/[SITE_ID]/detail.action?docID=1406285 https://www.vlebooks.com/vleweb/product/openreader?id=none&isbn=9781420008258&uid=none |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA-ygbiTnzi_KDLwVO1H0qYXD5bJUOZBpgwvJV-9KBvYboh_vS9p165zCGoPoQ0hoe-F95W830OoF0qmUsGFTZgvbNDX2OauTs6B7eMwphQ2oYHhQzB4wndjMq5D6Sa7JOeX4nNtXslfuAp9wFedJfsLzlaTQge8A3-hBQ5Du2L8Vp8LsKVZjZ9kQvGm4IOx48JMQ2pWpy6yDlE2PPr4MW7cvyhcPRd7hT9H1wo-zwDu92_uHYoj31QCrSV8de9OW_wwMmmMS-ZFZA4UWdvDgadlQ_xSGZUabiZYGFkFYjqYCA4pAUthuqvGdB3UYdkrSGiQ3nm2ggD7TeMZNT7aRm2lczt20Iaa7KLNYXmvYA_1lglqTVOrJuhFZpXk3EfPt_1RPLDL-hE284LI_bAFVmEIDh0jkmKqwbIEITSFh6dOxDVSjfSpg9MQ_MSQ-aCriU-EPvZWWEbMP0CtyXSiDpEF3SRShAtXV0J3aCS5xCzVqefgZMqgi86X_jqZv5mz7ixpcK6LrpeJkeQmKJMWFVSK8T9zqIusBfkSs0B5gxeGx-Ap63TYo_-ucYy26k15glr5-0ydguGV8zOzL74AlNQoTw |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=book&rft.title=Neurobiology+of+Huntington%27s+Disease&rft.date=2011-01-01&rft.pub=CRC+Press&rft.isbn=9781420008258&rft_id=info:doi/10.1201%2FEBK0849390005&rft.externalDocID=10_1201_EBK0849390005_version2 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fvle.dmmserver.com%2Fmedia%2F640%2F97814200%2F9781420008258.jpg |